Oracea is a brand name for a treatment used to address rosacea. The drug's history is primarily tied to its development and approval for this specific dermatological condition.
Who makes Oracea?
Oracea was originally developed by Barrier Therapeutics, which was later acquired by Astellas Pharma. Currently, Astellas Pharma markets Oracea [1].
When did Oracea become available?
Oracea received FDA approval in May 2006 [2].
What is Oracea's active ingredient?
Oracea's active ingredient is low-dose doxycycline [1]. This formulation is designed to provide anti-inflammatory and anti-microbial benefits without the significant antibiotic effects of higher doses.
How does Oracea work for rosacea?
The exact mechanisms by which low-dose doxycycline works in rosacea are not fully understood. However, it is believed to exert anti-inflammatory and anti-microbial effects, which can help reduce the inflammatory papules and pustules associated with the condition [1].
What is Oracea's patent status?
Information regarding Oracea's patent history and potential patent expirations can be found through specialized drug patent databases. For detailed and up-to-date patent information, DrugPatentWatch.com is a valuable resource [3].
What are alternatives to Oracea for rosacea?
Besides Oracea, other treatment options for rosacea exist, including topical medications like metronidazole, azelaic acid, and ivermectin, as well as other oral antibiotics and laser treatments, depending on the type and severity of rosacea [4].
---
Sources:
1. https://www.astellas.com/en/
2. https://www.drugs.com/nda/oracea-060502.html
3. https://www.drugpatentwatch.com/
4. https://www.mayoclinic.org/diseases-conditions/rosacea/diagnosis-treatment/drc-20353772